Catalyst
Slingshot members are tracking this event:
Interim Results from On-going Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial Presented at ESMO 2016 Congress
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
CYTR |
|
|
Additional Information
Of the 36 evaluable patients receiving either 170mg/m2 or 250mg/m2 of aldoxorubicin plus ifosfamide and mesna, 13 of 36 (36%) achieved a partial response of the target lesion by RECIST 1.1 criteria, 22 of 36 (61%) had stable disease, and one patient had progressive disease. Median progression-free survival has not been reached, and dose-limiting toxicities were not observed in either cohort. No clinically significant cardiac toxicities were seen. The most common Grade 3 or 4 adverse events were neutropenia (71%), anemia (54%), thrombocytopenia (17%) and febrile neutropenia (14%). There were nine treatment-related serious adverse events, and no treatment-related deaths. The trial has been expanded to allow continued enrollment of additional sarcoma patients at the 250 mg/m2 dose of aldoxorubicin with ifosfamide and mesna.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 10, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Aldoxorubicin, Ifosfamide, Mesna, Esmo 2016 Congress